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ABSTRACT
Objective: Given evidence from genetic studies, we hypothesized that there may be a shared com-
ponent to the role of myeloid function in Parkinson and Alzheimer disease (PD and AD) and as-
sessed whether PD susceptibility variants influenced protein expression of well-established
AD-associated myeloid genes in human monocytes.
Methods: We repurposed data in which AD-related myeloid proteins CD33, TREM1, TREM2,
TREML2, TYROBP, and PTK2B were measured by flow cytometry in monocytes from 176 partici-
pants of the PhenoGenetic Project (PGP) and Harvard Aging Brain Study. Linear regression was used
to identify associations between 24 PD risk variants and protein expression. The 2 cohorts were
meta-analyzed in a discovery analysis, and the 4 most strongly suggestive results were validated in
an independent cohort of 50 PGP participants.
Results: We discovered and validated an association between the PD risk allele rs12456492G in the
RIT2 locus and increased CD33 expression (pjoint 5 3.50 3 1025) and found strongly suggestive evi-
dence that rs11060180A in the CCDC62/HIP1R locus decreased PTK2B expression (pjoint 5 1.12 3
1024). Furthermore, in older individuals, increased CD33 expression on peripheral monocytes was asso-
ciated with a greater burden of parkinsonism (p 5 0.047), particularly bradykinesia (p 5 6.64 3 1023).
Conclusions: We find that the rs12456492 PD risk variant affects expression of AD-associated
protein CD33 in peripheral monocytes, which suggests that genetic factors for these 2 diseases
may converge to influence overlapping innate immune-mediated mechanisms that contribute to
neurodegeneration. Furthermore, the effect of the rs12456492G PD risk allele on increased
CD33 suggests that the inhibition of certain myeloid functions may contribute to PD suscepti-
bility, as is the case for AD. Neurol Genet 2016;2:e90; doi: 10.1212/NXG.0000000000000090
GLOSSARY
AD 5 Alzheimer disease; DLPFC 5 dorsolateral prefrontal cortex; eQTL5 expression quantitative trait locus; GWAS5 genome-
wide association study;HABS5HarvardAgingBrain Study;PD5 Parkinson disease;PGP5 PhenoGenetic Project; pQTL5 protein
quantitative trait locus;ROS-MAP5 ReligiousOrders Study andMemory andAging Project;SNP5 single nucleotide polymorphism.
Parkinson disease (PD) and Alzheimer disease (AD) are clinically distinct neurodegenerative dis-
eases; however, their pathologic features (e.g., Lewy bodies and tau tangles) and certain clinical
traits (e.g., parkinsonism and dementia) are often found together in older individuals with these
syndromic diagnoses.1–3 In addition, microglia and macrophages have been implicated in both
PD and AD pathogenesis, and the myeloid-specific gene TREM2 has been implicated in both PD
and AD susceptibility,4,5 suggesting a common role for the innate immune system in both
diseases.6–8 To underscore further a role for the innate immune system in both PD and AD,
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our group recently found that multiple PD and
AD susceptibility variants influenced the RNA
expression of nearby genes: they were cis-
expression quantitative trait loci (eQTLs) pri-
marily in monocytes.9,10 Thus, it appears that
the functional consequences of AD and PD risk
alleles may converge in influencing innate
immune pathways.11
Given the results of our initial eQTL analy-
sis, we hypothesized that PD-associated single
nucleotide polymorphisms (SNPs) could have
protein QTL effects with innate immune AD
susceptibility genes in trans. To test this, we
took advantage of a previously generated data
set of protein expression levels of AD-related
myeloid genes, TREML2, TREM1, TREM2,
TYROBP, PTK2B, and CD33 in monocytes
from 226 genotyped participants of the Pheno-
Genetic Project (PGP) and the Harvard Aging
Brain Study (HABS).12 In the analyses presented
here, we determined whether 24 validated PD
susceptibility SNPs (table 1) influenced the
expression of these 6 AD-related proteins in
a discovery analysis and then validated the top
results in an independent set of participants.
METHODS We used the same methodology as the one used in
a previous study.12 Additional information is included in the
e-Methods at Neurology.org/ng.
Standard protocol approvals and patient consent. Experi-
ments, including blood draws, brain autopsies, and data analysis,
were done in compliance with protocols approved by either the
Partners Human Research Committee or the Rush University
Institutional Review Board. Written, informed consent was ob-
tained from all participants.
PhenoGenetic Project. For this study, cryopreserved peripheral
blood mononuclear cells derived from healthy, genotyped participants
of the PGP, a living biobank, from Brigham and Women’s Hospital
in Boston, MA, were used. To date, 1,753 self-reported healthy
participants, ranging in age from 18 to 50, have been recruited. Of
the participants, 71% are Caucasian and 62.7% are female. For the
protein quantitative trait locus (pQTL) study performed herein, all
samples were derived from PGP participants of European ancestry
(n5 165). The EIGENSTRAT program was used with the genome-
wide genotype data to determine ancestry.
Harvard Aging Brain Study. Neuroimaging was used to iden-
tify cognitively nonimpaired, healthy older individuals with in-
creases in brain amyloid in the longitudinal HABS. Participants
range in age from 65 to 90. Currently, 276 participants are
enrolled in the study; 81% are Caucasian and 59.4% are female.
These individuals undergo clinical and neuroimaging evaluations,
as described previously.13 Of the HABS participants, 161 have
been genotyped, and the EIGENSTRAT program was used to
determine ancestry. All the individuals in the current study are of
European ancestry (n 5 61).
Religious Orders Study and Memory and Aging Project.
Similar to HABS, the Memory and Aging Project (MAP) and
Religious Orders Study (ROS) are longitudinal aging studies. Par-
ticipants are recruited while cognitively nonimpaired and
undergo annual clinical assessments in addition to agreeing to
donate their brains at the time of death under the Anatomic Gift
Act. Detailed antemortem clinical and neuropathologic assess-
ments are performed for each participant. Parkinsonism was as-
sessed by trained nurses at study entry and was based on 26
items from a modified version of the motor section of the Unified
Parkinson’s Disease Rating Scale.14 Four previously established
parkinsonian sign scores (bradykinesia, rigidity, tremor, and gait
disturbance) were derived from these 26 items, and a summary
global parkinsonian sign score was constructed by averaging these
4 scores, as detailed in prior publications.14,15 The retention rate
and autopsy rate of participants exceeds 90% and 80%, respec-
tively. A detailed report of MAP and ROS can be found else-
where.16–18 All individuals with CD33 monocyte surface protein
expression (n 5 151) and those with PTK2B RNA expression
from the dorsolateral prefrontal cortex (DLPFC) (n 5 508) were
determined to be of European ancestry by using EIGENSTRAT.
Table 1 Parkinson disease variants examined in
protein quantitative trait locus analysis
SNP Locus
Alleles
(ref/other)
rs10797576 SIPA1L2 C/T
rs11060180 CCDC62/HIP1R A/G
rs11158026 GCH1 C/T
rs11724635 BST1 C/A
rs117896735 INPP5F G/A
rs11868035 SREBF1-RAI1 G/A
rs12456492 RIT2 A/G
rs12637471 MCCC1 G/A
rs14235 BCKDK-STX1B G/A
rs1474055 STK39 C/T
rs199347 GPNMB A/G
rs2414739 VPS13C G/A
rs329648 MIR4697 T/C
rs34311866 TMEM175-GAK-DGKQ T/C
rs356182 SNCA G/A
rs35749011 GBA-SYT11 G/A
rs591323 FGF20 G/A
rs6430538 ACMSD-TMEM163 C/T
rs6812193 FAM47E-SCARB2 C/T
rs76904798 LRRK2 C/T
rs8118008 DDRGK1 A/G
rs823118 RAB7L1-NUCKS1 C/T
rs17649553a MAPT C/T
rs9275326b HLA-DQB1 C/T
All single nucleotide polymorphisms (SNPs) were p # 0.05
in the replication phase of Nalls et al.19
aUsed proxy variant rs113579895.
bUsed proxy variant rs115462410.
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Statistical analysis. In summary, 24 SNPs previously identified
in a PD genome-wide association study (GWAS)19 were selected
for the study. Our analysis was limited to 144 SNP:protein pairs
(24 SNPs3 6 proteins) in the discovery phase. Four SNP:protein
pairs with the lowest, most suggestive p values were selected for
follow-up in the validation phase. To identify statistically
significant trans associations, we used a Bonferroni significance
threshold of p # 0.003 (p # 0.01/4).
Flow cytometry protein expression was collected in discrete ex-
periments. Each experiment consisted of multiple batches, which
contained 7–12 participants per batch. The discovery data set con-
sisted of 176 unique PGP individuals (n5 115) as well as the HABS
cohort (n5 61) separated into 4 experiments. The validation cohort
included 50 unique PGP participants and was analyzed in a single
experiment. PTK2B was not measured in 49 PGP individuals, cre-
ating a PTK2B discovery sample size of n5 127 and a total of n5
177. Prior to the meta-analysis of all experiments, each experiment
was analyzed separately. In each experiment, expression levels were
gaussianized using equation 1, thus decreasing the weight and poten-
tial bias of any outlying observations.
Ytijk 5u
2 1
 
rijk 2 3=8

Njk 2 6=81 1
!
(1)
rijk 5 rank, Njk 5 sample size, and Yijk 5 expression level; where
i indexes participants, j indexes experiment, and k indexes
protein.
Before analyzing each SNP:protein combination, we imple-
mented Combat version 2.0 (with the sva R package20) to control
for batch. Each SNP:protein combination was then analyzed via
linear regression with expression modeled as the outcome and
SNP modeled as the predictor variable. To reduce potential con-
founding, we also included cell viability, age, and sex in the linear
model. This was done for each experiment. The resulting
t statistic for each pQTL combination was then meta-analyzed
using the Stouffer method (equation 2), providing discovery
p values. The Stouffer method is commonly used in GWAS
meta-analysis.21 To validate the SNP:protein combinations cho-
sen from discovery, we applied the same transformations and
linear regression analysis that was used in discovery. After the
validation analysis was complete, we meta-analyzed across all 5
experiments to produce ultimate joint p values. To check for
possible inflation of type I error, we also determined empirical
p values via permutation analysis, repeating the analysis 10,000
times after randomly sampling genotypes.
Before analyzing ROS-MAP mRNA levels as measured by
RNA-seq, multiple QC steps were taken. First, using Combat
to adjust for batch, FPKM values were quantile-normalized. Sec-
ond, the effects of technical and demographic factors (RNA integ-
rity number, log2(total aligned reads), postmortem interval, age,
sex, cohort, genotype PCs, and genotyping platform) were
removed by creating residuals with linear regression, using
mRNA expression as the outcome variable. These residuals were
then gaussianized by using equation 1. R was used in all statistical
analysis, and GraphPad Prism 6 was used for all plots.
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RESULTS Protein expression of genes thought to
be important for AD (TREML2, TREM1, TREM2,
TYROBP, and CD33) was previously measured using
flow cytometry in primary human monocytes from
115 younger, healthy participants of PGP and 61
older, cognitively nonimpaired participants from
HABS in a quantitative trait study with AD suscep-
tibility variants; PTK2B protein expression was also
measured in a subset of 66 PGP participants and in all
HABS participants.12 We repurposed this data set to
determine whether the 24 PD susceptibility variants pre-
viously identified in GWAS (table 1) were associated
with measured protein expression. We meta-analyzed
the 2 cohorts (PGP and HABS) in a discovery phase
analysis to identify suggestive results and then validated
these results in an independent cohort consisting of 50
PGP participants. A joint analysis combining individuals
from the discovery and validation phases was also
performed to summarize all available data. Together,
the 165 PGP participants had a mean age of 33.7
(610.59) years and were 40.6% male, while HABS
participants had a mean age of 76.3 (66.08) years and
were 50.8% male.
In the discovery phase, 4 PD SNP:AD protein
pairs with the lowest, most suggestive p values
(rs11060180:CD33 [pdisc_meta 5 7.38 3 1024],
rs12456492:CD33 [pdisc_meta 5 2.14 3 1023],
rs11060180:PTK2B [pdisc_meta 5 0.011], and
rs12637471:TYROBP [pdisc_meta 5 0.011] [table 2;
table e-1]) were selected for validation in an independent
experiment (n 5 50). Among the 4 SNP:protein pairs,
only the rs12456492:CD33 association was validated
after Bonferroni correction (pcut-off # 2.5 3 1023
[p # 0.01/4]) (pval 5 2.39 3 1023, pjoint 5 3.50 3
1025; table 2; table e-2) with the direction of effect being
consistent in the discovery and validation analyses.
Although the influence of rs11060180 on PTK2B
expression was only suggestive in the validation phase
(pval5 0.028; table 2), it was the only other association
aside from rs12456492:CD33 in the joint analysis to
pass the global Bonferroni threshold (pjoint 5 1.12 3
1024; table 2; table e-3) and had a consistent direction
of effect in both data sets. Furthermore, we applied
Table 2 Summary of top protein quantitative trait locus effects
SNP Locus Protein pdisca pvalb pjointc
rs11060180 CCDC62/HIP1R CD33 7.38 3 1024 0.572 6.68 3 1023
rs12456492 RIT2 CD33 2.14 3 1023 2.39 3 1023 3.50 3 1025
rs11060180 CCDC62/HIP1R PTK2B 0.011 0.028 1.12 3 1024
rs12637471 MCCC1 TYROBP 0.011 0.253 5.43 3 1023
Abbreviations: HABS 5 Harvard Aging Brain Study; PGP 5 PhenoGenetic Project; SNP 5
single nucleotide polymorphism.
Complete results can be found in tables e-1–e-3.
aMeta-analysis p value for the discovery phase (discovery PGP and HABS participants
combined).
b The 4 associations were tested independently in a validation phase (Bonferroni cutoff is
p # 2.5 3 1023 [p # 0.01/4]).
c Joint p value combining discovery and validation phases.
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a permutation-based analysis to all 144 hypotheses tested,
in which the false discovery rate (FDR) was derived from
10,000 permutations of the data (genotype was per-
muted). In this analysis, both the rs11060180:PTK2B
and rs12456492:CD33 associations were the only asso-
ciations to yield FDR #0.05 (table e-4). Thus, our 2
main results were unlikely to be chance observations.
Consistent with the previously reported rs3865444C
CD33 AD risk allele,13 the PD risk allele rs12456492G
in the RIT2 locus was associated with increased CD33
surface expression on monocytes (figure, A) and ex-
plained 7.6% of the variance in CD33. Conversely,
the suggestive rs11060180A risk allele near CCDC62/
HIP1R was associated with decreased PTK2B expression
(figure, B) and explained 8.5% of the variance in
PTK2B; this result contrasts with the PTK2B and
NME8 AD susceptibility variants rs28834970C and
rs2718058A, respectively, which we have previously re-
ported to be associated with higher levels of PTK2B
expression in this data set.12 To determine whether these
trans associations were present at the mRNA level, we
analyzed mRNA expression in monocyte ImmVar data13
and in DLPFC tissue from the Religious Orders Study
and Memory and Aging Project (ROS-MAP). Brain
tissue was analyzed because infiltrating CNS monocytes
and brain-resident microglia, cell types that are known to
express the measured proteins, are thought to play a crit-
ical role in the accumulation of AD pathology. Neither
rs12456492 nor rs11060180 had an association with
CD33 or PTK2BmRNA, respectively, in either data set.
Intrigued by the evidence suggesting that AD-
associated proteins CD33 and PTK2B may play
a role in PD, we examined the extent of association
of PD-related pathologic (neuronal loss in the sub-
stantia nigra, burden of Lewy bodies) and clinical (par-
kinsonism as well as its component measures of
bradykinesia, rigidity, and gait impairment) traits with
ROS-MAP monocyte CD33 surface expression (repur-
posing a previous data set13) and ROS-MAP DLPFC
PTK2B mRNA expression (the only PTK2B expression
data available from this cohort). We did not observe an
association of PTK2B mRNA expression in DLPFC
with these traits. However, we did note a nominal asso-
ciation of increasing CD33 monocyte protein surface
expression with a greater global measure of parkinson-
ism (p5 0.047) that appeared to be primarily driven by
an effect on bradykinesia (p 5 6.64 3 1023).
DISCUSSION We conducted a trans-pQTL study in
human ex vivo monocytes examining the relationship
between PD risk variants and expression of AD-related
proteins TREM1, TREM2, TREML2, TYROBP,
PTK2B, and CD33 to detect whether AD and PD
pathophysiology share common innate immune
mechanisms. We discovered that the PD risk allele
rs12456492G in the RIT2 locus was associated with
increased CD33 surface expression and found highly
suggestive evidence that the rs11060180A PD risk allele
in the CCDC62/HIP1R locus was associated with lower
PTK2B expression. Of interest, these trans associations
were not observed at the mRNA level, highlighting the
importance of protein-level QTL studies, which can
capture effects of posttranslational regulation.22
PTK2B, a member of the focal adhesion kinase
family, is a protein tyrosine kinase that is rapidly acti-
vated by a number of mediators including lipopolysac-
charide, cytokines, and cell adhesion23,24 and is thought
to play an important role in the phagocytosis and
migration of monocytes and macrophages through its
involvement in cytoskeletal signaling pathways.25 In
a GWAS, rs28834970 in the PTK2B locus was iden-
tified as having a significant association with AD sus-
ceptibility,26 and we have been able to confirm that
rs28834970 has both a cis-eQTL and cis-pQTL effect
on PTK2B expression in monocytes.9,16 Although the
effect of the CCDC62/HIP1R rs11060180 PD risk
allele on decreasing PTK2B is opposite of that in AD
Figure Parkinson disease risk variants influence
expression of Alzheimer-related
proteins CD33 and PTK2B in human
monocytes
(A) CD33 and (B) PTK2B protein expression in monocytes
was quantified through flow cytometry and plotted against
each participant’s rs12456492 and rs11060180 geno-
type, respectively; the y-axis represents normalized median
fluorescence intensity (MFI) and the horizontal line denotes
mean MFI. Each dot represents one individual from either
the PhenoGenetic Project (PGP) or Harvard Aging Brain
Study (HABS) cohort.
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(in which risk variants are associated with increased
PTK2B), the effect of rs11060180 was consistent
across our discovery and validation studies. Thus, while
certain immune molecular pathways may be impli-
cated in both PD and AD, they may not have the same
role in the 2 diseases. This is not unlike a number of
susceptibility alleles that are associated with different
inflammatory diseases but have effects in opposite di-
rections (being risk-associated for one disease and pro-
tective for another).12,27 In addition, we did not detect
an association between PTK2BmRNA cortical expres-
sion and PD-related traits in the ROS-MAP cohort;
however, an analysis of a PD-specific cohort would
provide a complementary analysis that would be more
relevant for the context of PD.
The AD-associated protein CD33 is a siglec ex-
pressed on the surface of myeloid cells and contains
putative immunoreceptor tyrosine–based inhibitory
motifs that are known to suppress cellular activity
such as proinflammatory cytokine secretion and amy-
loid beta uptake.13,28 Not only has CD33 been impli-
cated in AD through GWAS26,29–31 but the effect of
the CD33 rs3865444C risk allele on increased CD33
protein expression13,32 as well as CD33’s effect on
amyloid accumulation in humans and mouse models
of AD13,33 has been reported. In our study, we found
that the rs12456492G Parkinson risk allele in the
RIT2 locus was associated with increased CD33
expression, consistent with the CD33 AD risk allele,
which suggests that myeloid suppression is associated
with PD susceptibility, as is the case for AD. Of note,
we found that CD33 protein surface expression on
monocytes of older individuals was modestly associ-
ated with bradykinesia, implicating CD33 in PD
pathogenesis in addition to AD. These intriguing re-
sults will be important in guiding future studies
examining the role of CD33 in both diseases.
Growing evidence indicates that the innate
immune system plays an important role in PD and
AD pathophysiology, but it remains unclear whether
overlapping signaling pathways are involved. Our
pQTL study revealing that the AD-associated protein
CD33 is modulated by a PD susceptibility locus and
that increased CD33 monocyte surface expression is
correlated with both PD and AD clinical traits sug-
gests that, although PD and AD causal variants are
distinct, some of them may converge on the same sig-
naling pathways. Furthermore, the association of
increased CD33 with PD risk provides the insight
that myeloid suppression is a risk factor for PD. It
is also not clear whether the effects we report in
peripheral monocytes contribute to PD directly by
influencing the behavior of infiltrating cells that dif-
ferentiate into macrophages or whether these associa-
tions reflect shared effects with resident microglia.
While we report some overlap between the effects
of AD and PD variants in monocytes, it is important
to note that the bulk of the monocyte molecular path-
ways implicated in each disease appears to be unique
(as evidenced by opposing relationships in PTK2B
expression between PD and AD risk alleles), which
suggests that therapeutic approaches to target immune
pathways in PD and AD may have to be considered
carefully to avoid provoking another neurodegenera-
tive process as an adverse event. Although more work
will be needed to verify these associations in macro-
phages and microglia at the sites of pathology, our
findings begin to shed light onto common immune
mechanisms contributing to both PD and AD, which
may aid in the development of therapeutic strategies
used to target each disease.
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